Becton, Dickinson Achieves Analyst Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy BDX?
Source: NASDAQ.COM
Stock Performance: Becton, Dickinson & Co (BDX) shares have surpassed the average analyst 12-month target price of $200.40, currently trading at $200.43/share.
Analyst Reactions: Analysts may respond to the stock reaching the target price by either downgrading their valuation or raising their target price, depending on the company's fundamental developments.
Diverse Analyst Targets: Within the Zacks coverage universe, analyst targets for BDX vary significantly, with one as low as $183.00 and another as high as $230.00, indicating a standard deviation of $15.536.
Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on track for further gains or if it’s time to consider selling some shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 210.020
Low
183.00
Averages
202.38
High
220.00
Current: 210.020
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
Becton Dickinson Reports Strong Q1 2026 Earnings Exceeding Expectations
- Strong Performance: Becton Dickinson reported Q1 revenues of $5.3 billion, reflecting a 0.4% year-over-year growth, with New BD achieving a 2.5% increase, showcasing robust performance in biologic drug delivery and pharmacy automation, thereby reinforcing its market position.
- Margin Performance: The adjusted gross margin stood at 53.4%, down 140 basis points from the previous year, yet still above expectations, indicating the company's ongoing efforts in productivity and cost control to maintain profitability stability.
- Strategic Transaction: The company announced the imminent completion of its Life Sciences business merger with Waters, expected to yield a $4 billion cash distribution, with $2 billion allocated for share repurchases and $2 billion for debt repayment, further optimizing its capital allocation strategy.
- Future Outlook: Management anticipates low single-digit revenue growth for New BD in fiscal 2026, providing adjusted EPS guidance in the range of $12.35 to $12.65, reflecting confidence in future performance despite tariff impacts.
See More
US Stocks Dip Slightly as Tech Shares Retreat
- Tech Stock Retreat: Technology stocks are broadly down today, contributing to a 0.03% decline in the S&P 500, a 0.34% drop in the Dow Jones, and a 0.17% decrease in the Nasdaq 100, reflecting a cautious investor sentiment following last Friday's sharp gains.
- Bond Yield Pressure: Rising US bond yields, with the 10-year T-note yield up 2 basis points to 4.22%, are exacerbated by Chinese regulators instructing banks to reduce their US debt holdings, reviving concerns over the haven status of US assets and potentially impacting investor confidence.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth is projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating resilience in corporate earnings and potential market support.
- Economic Data Focus: The market is set to focus on upcoming economic data, including a projected 0.8% increase in the employment cost index on Tuesday and a 2.5% year-over-year rise in the consumer price index on Friday, which will provide guidance on future economic trends.
See More
Becton Dickinson BDX Q1 2026 Earnings Transcript
See More
Becton Dickinson Reports Sales Above Expectations
- Strong Sales Performance: Becton Dickinson reported sales of $5.25 billion, slightly exceeding the consensus of $5.15 billion, indicating the company's stable demand and adaptability in the healthcare sector.
- Segment Performance: The Medical Essentials segment saw a 0.6% sales increase to $1.595 billion, despite impacts from order timing and market share dynamics in China, while U.S. Vascular Access Management continued to gain market share.
- Adjusted Earnings Guidance: The company lowered its fiscal 2026 adjusted earnings guidance to $12.35-$12.65 per share, below the consensus of $14.72, reflecting uncertainties in future market demand.
- Market Reaction: Becton Dickinson's shares fell 3.77% to $202.10 in premarket trading, indicating investor concerns over the company's high valuation despite a healthy balance sheet.
See More
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
Becton Dickinson Reports Strong Q1 2026 Earnings Exceeding Expectations
- Strong Performance: Becton Dickinson reported Q1 revenues of $5.3 billion, reflecting a 0.4% year-over-year growth, with New BD achieving a 2.5% increase, showcasing robust performance in biologic drug delivery and pharmacy automation, thereby reinforcing its market position.
- Margin Performance: The adjusted gross margin stood at 53.4%, down 140 basis points from the previous year, yet still above expectations, indicating the company's ongoing efforts in productivity and cost control to maintain profitability stability.
- Strategic Transaction: The company announced the imminent completion of its Life Sciences business merger with Waters, expected to yield a $4 billion cash distribution, with $2 billion allocated for share repurchases and $2 billion for debt repayment, further optimizing its capital allocation strategy.
- Future Outlook: Management anticipates low single-digit revenue growth for New BD in fiscal 2026, providing adjusted EPS guidance in the range of $12.35 to $12.65, reflecting confidence in future performance despite tariff impacts.
See More
US Stocks Dip Slightly as Tech Shares Retreat
- Tech Stock Retreat: Technology stocks are broadly down today, contributing to a 0.03% decline in the S&P 500, a 0.34% drop in the Dow Jones, and a 0.17% decrease in the Nasdaq 100, reflecting a cautious investor sentiment following last Friday's sharp gains.
- Bond Yield Pressure: Rising US bond yields, with the 10-year T-note yield up 2 basis points to 4.22%, are exacerbated by Chinese regulators instructing banks to reduce their US debt holdings, reviving concerns over the haven status of US assets and potentially impacting investor confidence.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth is projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating resilience in corporate earnings and potential market support.
- Economic Data Focus: The market is set to focus on upcoming economic data, including a projected 0.8% increase in the employment cost index on Tuesday and a 2.5% year-over-year rise in the consumer price index on Friday, which will provide guidance on future economic trends.
See More
Becton Dickinson BDX Q1 2026 Earnings Transcript
See More
Becton Dickinson Reports Sales Above Expectations
- Strong Sales Performance: Becton Dickinson reported sales of $5.25 billion, slightly exceeding the consensus of $5.15 billion, indicating the company's stable demand and adaptability in the healthcare sector.
- Segment Performance: The Medical Essentials segment saw a 0.6% sales increase to $1.595 billion, despite impacts from order timing and market share dynamics in China, while U.S. Vascular Access Management continued to gain market share.
- Adjusted Earnings Guidance: The company lowered its fiscal 2026 adjusted earnings guidance to $12.35-$12.65 per share, below the consensus of $14.72, reflecting uncertainties in future market demand.
- Market Reaction: Becton Dickinson's shares fell 3.77% to $202.10 in premarket trading, indicating investor concerns over the company's high valuation despite a healthy balance sheet.
See More
